Intra-Cellular Therapies Inc. (NASDAQ:ITCI) – Equities researchers at Leerink Swann raised their FY2016 earnings per share estimates for shares of Intra-Cellular Therapies in a research note issued on Thursday. Leerink Swann analyst S. Fernandez now forecasts that the firm will post earnings of ($2.82) per share for the year, up from their previous forecast of ($3.41). Leerink Swann has a “Outperform” rating and a $29.00 price objective on the stock. Leerink Swann also issued estimates for Intra-Cellular Therapies’ Q4 2016 earnings at ($0.78) EPS, FY2017 earnings at ($3.36) EPS, FY2018 earnings at ($3.89) EPS, FY2019 earnings at ($3.97) EPS and FY2020 earnings at ($2.83) EPS.

A number of other research firms also recently issued reports on ITCI. Piper Jaffray Cos. reiterated an “overweight” rating and set a $57.00 price objective on shares of Intra-Cellular Therapies in a research note on Tuesday, September 13th. JMP Securities downgraded shares of Intra-Cellular Therapies from an “outperform” rating to a “market perform” rating in a research note on Thursday, September 29th. Royal Bank Of Canada lowered their target price on shares of Intra-Cellular Therapies from $74.00 to $49.00 and set an “outperform” rating for the company in a research note on Thursday, September 29th. SunTrust Banks Inc. downgraded shares of Intra-Cellular Therapies from a “buy” rating to a “neutral” rating and lowered their target price for the company from $60.00 to $15.00 in a research note on Thursday, September 29th. Finally, Cowen and Company restated a “buy” rating and issued a $75.00 target price on shares of Intra-Cellular Therapies in a research note on Friday, August 5th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $42.00.

Earnings History and Estimates for Intra-Cellular Therapies (NASDAQ:ITCI)

Shares of Intra-Cellular Therapies (NASDAQ:ITCI) opened at 13.91 on Monday. Intra-Cellular Therapies has a 12 month low of $10.80 and a 12 month high of $59.96. The company’s market cap is $601.86 million. The stock’s 50 day moving average is $15.07 and its 200-day moving average is $33.02.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings data on Wednesday, November 9th. The biopharmaceutical company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.14. The business had revenue of $4.36 million for the quarter, compared to the consensus estimate of $0.04 million. During the same period in the previous year, the firm earned ($0.91) EPS. The company’s revenue was up NaN% on a year-over-year basis.

Several hedge funds and other institutional investors have recently bought and sold shares of ITCI. Ameriprise Financial Inc. boosted its position in Intra-Cellular Therapies by 1.8% in the second quarter. Ameriprise Financial Inc. now owns 8,460 shares of the biopharmaceutical company’s stock worth $328,000 after buying an additional 150 shares in the last quarter. Royal Bank of Canada boosted its position in shares of Intra-Cellular Therapies by 23.1% in the second quarter. Royal Bank of Canada now owns 2,684 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 504 shares during the period. Teacher Retirement System of Texas boosted its position in shares of Intra-Cellular Therapies by 13.7% in the second quarter. Teacher Retirement System of Texas now owns 4,532 shares of the biopharmaceutical company’s stock valued at $176,000 after buying an additional 546 shares during the period. Mycio Wealth Partners LLC boosted its position in shares of Intra-Cellular Therapies by 14.3% in the second quarter. Mycio Wealth Partners LLC now owns 4,398 shares of the biopharmaceutical company’s stock valued at $171,000 after buying an additional 550 shares during the period. Finally, California State Teachers Retirement System boosted its position in shares of Intra-Cellular Therapies by 1.0% in the third quarter. California State Teachers Retirement System now owns 72,665 shares of the biopharmaceutical company’s stock valued at $1,107,000 after buying an additional 700 shares during the period. 65.39% of the stock is owned by institutional investors and hedge funds.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

5 Day Chart for NASDAQ:ITCI

Receive News & Stock Ratings for Intra-Cellular Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies Inc. and related stocks with our FREE daily email newsletter.